Maloney

December 29, 2022

Congressional investigation into Alzheimer’s drug Aduhelm objects to FDA and Biogen

[ad_1] The report said the FDA’s approval process for Aduhelm was “riddled with irregularities” and criticized Biogen for setting an “unjustifiably high price.” [ad_2] Source link
Congressional investigation into Alzheimer’s drug Aduhelm objects to FDA and Biogen
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more